Medical oncologists Lucio N. Gordan, MD and Ivor Percent, MD, members of the clinical research team at Florida Cancer Specialists & Research Institute (FCS), are co-authors for a study that examined the safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma (nccRCC) administered primarily in community-based settings.
Lime Connect (Lime) is pleased to announce that Nathan H. Walcker, Chief Executive Officer of Florida Cancer Specialists & Research Institute, has joined the not for profit organization as a member of its global board of directors.
Hodgkin lymphoma, named after Dr. Thomas Hodgkin, is a cancer that affects the lymphatic system which makes up part of the body’s immune system. Specifically, Hodgkin lymphoma occurs when the DNA changes in white blood cells called lymphocytes.
The survival rate for Americans diagnosed with several of the most common cancers has increased dramatically in the past nearly three decades, thanks in large part to scientific discoveries and treatment advances. Florida Cancer Specialists & Research Institute (FCS) physicians and patients are part of these leading-edge cancer innovations.
Florida Cancer Specialists & Research Institute, LLC (FCS) medical oncologists Ivor Percent, MD, Maen Hussein, MD, and Viralkumar Bhanderi, MD, contribute observations for Phase II study. Another presentation at ASCO GI 2022 includes Phase I observations from FCS physician, Manish R. Patel, MD.
A variety of drugs are used to treat cancer. Delivered by infusions, injections, or taken orally, it takes a range of specially trained professionals working together to ensure that these pharmaceuticals are used safely and effectively so that patients achieve optimal clinical outcomes.
FCS Top News Updates
FCS Welcomes Arushi Thaper, MD to Orange County Team
Lucio Gordan, MD, Ivor Percent, MD Co-Author Phase 3b/4 Renal Cell Carcinoma StudyMedical oncologists Lucio N. Gordan, MD and Ivor Percent, MD, members of the clinical research team at Florida Cancer Specialists & Research Institute (FCS), are co-authors for a study that examined the safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma (nccRCC) administered primarily in community-based settings.
Nathan H. Walcker joins Lime Connect Global Board of DirectorsLime Connect (Lime) is pleased to announce that Nathan H. Walcker, Chief Executive Officer of Florida Cancer Specialists & Research Institute, has joined the not for profit organization as a member of its global board of directors.
FCS Spotlight: Meet Dr. Katy Phelan, Genetics Lab DirectorDr. Phelan identified the chromosome variant now known as Phelan-McDermid Syndrome
Florida Cancer Specialists & Research Institute Announces Senior Leadership AppointmentFCS announced the newest addition to its senior management team. Joshua Eaves joined FCS as Senior Vice President Corporate Development.
Understanding Hodgkin LymphomaHodgkin lymphoma, named after Dr. Thomas Hodgkin, is a cancer that affects the lymphatic system which makes up part of the body’s immune system. Specifically, Hodgkin lymphoma occurs when the DNA changes in white blood cells called lymphocytes.
Advancing Therapies for Patients Through Clinical Research in Community Oncology PracticesThe survival rate for Americans diagnosed with several of the most common cancers has increased dramatically in the past nearly three decades, thanks in large part to scientific discoveries and treatment advances. Florida Cancer Specialists & Research Institute (FCS) physicians and patients are part of these leading-edge cancer innovations.
Florida Cancer Specialists Physician Studies Featured at American Society of Clinical Oncology 2022 Gastrointestinal Cancers SymposiumFlorida Cancer Specialists & Research Institute, LLC (FCS) medical oncologists Ivor Percent, MD, Maen Hussein, MD, and Viralkumar Bhanderi, MD, contribute observations for Phase II study. Another presentation at ASCO GI 2022 includes Phase I observations from FCS physician, Manish R. Patel, MD.
Pharmacists in the Front-Line: The Fight Against CancerA variety of drugs are used to treat cancer. Delivered by infusions, injections, or taken orally, it takes a range of specially trained professionals working together to ensure that these pharmaceuticals are used safely and effectively so that patients achieve optimal clinical outcomes.